Middle East Respiratory Syndrome (MERS) (Coronaviruses)

Overview

Plain-Language Overview

Middle East Respiratory Syndrome (MERS) is a viral infection that primarily affects the lungs and respiratory system. It is caused by a coronavirus that can lead to severe breathing difficulties and pneumonia. People infected with MERS often experience symptoms like fever, cough, and shortness of breath. The virus spreads mainly through close contact with infected individuals or animals, especially camels. MERS can cause serious illness, particularly in older adults or those with weakened immune systems, and may require hospitalization.

Clinical Definition

Middle East Respiratory Syndrome (MERS) is a severe respiratory illness caused by the MERS coronavirus (MERS-CoV), a zoonotic virus transmitted from dromedary camels to humans and via human-to-human contact. The infection primarily targets the lower respiratory tract, leading to acute viral pneumonia and potentially progressing to acute respiratory distress syndrome (ARDS) and multi-organ failure. The disease is characterized by symptoms such as fever, cough, and dyspnea, with a high case fatality rate compared to other coronaviruses. MERS-CoV is an enveloped, positive-sense single-stranded RNA virus belonging to the Betacoronavirus genus. The virus binds to the DPP4 (dipeptidyl peptidase 4) receptor on host cells, facilitating viral entry and replication. MERS is of major clinical significance due to its potential for outbreaks with high mortality and limited specific antiviral treatment options.

Inciting Event

Zoonotic transmission from infected dromedary camels through respiratory droplets or direct contact.
Human-to-human transmission via respiratory droplets in close contact settings, especially healthcare facilities.
Exposure to contaminated surfaces or fomites in endemic areas can initiate infection.

Latency Period

The incubation period ranges from 2 to 14 days, typically around 5-7 days before symptom onset.
Asymptomatic or mild infections may have a shorter or unrecognized latency period.

Diagnostic Delay

Initial symptoms mimic common respiratory infections leading to misdiagnosis as influenza or pneumonia.
Limited awareness and testing availability outside endemic regions delay MERS-CoV identification.
Overlap with other coronavirus infections causes diagnostic confusion without specific PCR testing.
Mild or atypical presentations in younger or healthier patients reduce clinical suspicion.

Clinical Presentation

Signs & Symptoms

High fever and chills are hallmark initial symptoms of MERS.
Cough and dyspnea develop as the infection progresses to lower respiratory tract involvement.
Myalgia and fatigue are common systemic symptoms.
Gastrointestinal symptoms such as diarrhea and vomiting can occur in some patients.
Severe cases may present with acute respiratory distress syndrome (ARDS) and multi-organ failure.

History of Present Illness

Initial symptoms include fever, cough, and myalgia progressing over days.
Rapid development of dyspnea and hypoxia often occurs within the first week.
Some patients develop gastrointestinal symptoms such as diarrhea and vomiting early in illness.
Severe cases progress to acute respiratory distress syndrome (ARDS) and multi-organ failure.
Symptom progression is typically subacute, worsening over 5-10 days after onset.

Past Medical History

History of chronic diseases such as diabetes mellitus, chronic kidney disease, or chronic lung disease increases risk of severe MERS.
Previous immunosuppressive therapy or conditions like cancer predispose to worse outcomes.
Prior exposure to healthcare settings or outbreaks may increase risk of infection.
No specific genetic predisposition has been definitively linked to MERS susceptibility.

Family History

No known heritable syndromes or familial patterns are associated with MERS.
Clusters of cases may occur in families due to shared exposure rather than genetic factors.
Family members of infected patients are at risk through close contact transmission.

Physical Exam Findings

Fever and tachypnea are common findings in patients with Middle East Respiratory Syndrome (MERS).
Crackles or rales may be auscultated due to viral pneumonia.
Hypoxia with decreased oxygen saturation is often present in severe cases.
Tachycardia may be observed secondary to fever and respiratory distress.
Signs of respiratory distress such as use of accessory muscles and nasal flaring can be present.

Diagnostic Workup

Diagnostic Criteria

Diagnosis of MERS is established by detecting MERS-CoV RNA using real-time reverse transcriptase polymerase chain reaction (RT-PCR) from respiratory specimens such as nasopharyngeal swabs, sputum, or bronchoalveolar lavage. Clinical suspicion arises in patients with acute respiratory illness and epidemiologic risk factors such as recent travel to the Arabian Peninsula or contact with camels or confirmed cases. Laboratory findings may include lymphopenia and elevated inflammatory markers, but confirmation relies on molecular testing. Serologic testing can support diagnosis retrospectively but is not used for acute diagnosis.

Pathophysiology

Key Mechanisms

Viral entry via the dipeptidyl peptidase 4 (DPP4) receptor on respiratory epithelial cells initiates infection.
Replication of the single-stranded RNA coronavirus within host cells leads to cytopathic effects and cell death.
Immune dysregulation causes a hyperinflammatory response with elevated cytokines contributing to lung injury.
Diffuse alveolar damage results in impaired gas exchange and acute respiratory distress syndrome (ARDS).
Multiorgan involvement occurs due to systemic viral dissemination and inflammatory cytokine effects.

Involvement	Details
Organs	Lungs are the primary organs affected, with manifestations ranging from pneumonia to acute respiratory distress syndrome.
Organs	Kidneys may be involved in severe cases causing acute kidney injury due to systemic inflammation and viral effects.
Tissues	Pulmonary alveolar tissue is the main site of viral replication and inflammatory damage causing respiratory symptoms.
Tissues	Endothelial tissue involvement contributes to vascular leakage and acute respiratory distress syndrome.
Cells	Alveolar epithelial cells serve as the primary target for MERS-CoV infection leading to lung injury.
	Macrophages contribute to the inflammatory response and cytokine release in infected lung tissue.
	T lymphocytes are involved in the adaptive immune response but may be depleted in severe cases.
Chemical Mediators	Interleukin-6 (IL-6) is elevated and correlates with disease severity and systemic inflammation.
	Tumor necrosis factor-alpha (TNF-α) mediates lung tissue damage and systemic inflammatory response.
	Interferons are part of the antiviral defense but may be suppressed by MERS-CoV.

Treatments

Pharmacological Treatments

Supportive care with oxygen therapy
- Mechanism:
  - Provides supplemental oxygen to maintain adequate tissue oxygenation in respiratory failure
- Side effects:
  - Oxygen toxicity with prolonged high concentrations
- Clinical role:
  - First-line
Mechanical ventilation
- Mechanism:
  - Supports breathing in patients with severe respiratory distress or failure
- Side effects:
  - Ventilator-associated pneumonia
  - Barotrauma
- Clinical role:
  - Supportive
Ribavirin
- Mechanism:
  - Nucleoside analog that inhibits viral RNA synthesis
- Side effects:
  - Hemolytic anemia
  - Teratogenicity
- Clinical role:
  - Adjunctive
Interferon alfa
- Mechanism:
  - Enhances antiviral immune response by stimulating interferon pathways
- Side effects:
  - Flu-like symptoms
  - Myelosuppression
- Clinical role:
  - Adjunctive

Non-pharmacological Treatments

Strict isolation and infection control measures to prevent nosocomial transmission of MERS-CoV.
Supportive care including fluid management and hemodynamic support in critically ill patients.
Use of personal protective equipment by healthcare workers to reduce spread.

Prevention

Pharmacological Prevention

No approved antiviral prophylaxis exists for MERS-CoV infection.
Experimental vaccines are under development but not yet available for clinical use.
Post-exposure prophylaxis with antivirals is not established and not routinely recommended.

Non-pharmacological Prevention

Strict hand hygiene and use of personal protective equipment (PPE) reduce transmission risk.
Isolation of infected patients and airborne precautions prevent nosocomial spread.
Avoidance of contact with camels and camel products in endemic areas decreases zoonotic transmission.
Screening and monitoring of travelers from endemic regions help early detection and containment.

Outcome & Complications

Complications

Acute respiratory distress syndrome (ARDS) is a major life-threatening complication of MERS.
Sepsis and septic shock can develop due to systemic viral infection and secondary bacterial infections.
Multi-organ failure including acute kidney injury and liver dysfunction occurs in severe cases.
Secondary bacterial pneumonia is a common complication worsening clinical course.

Short-term Sequelae	Long-term Sequelae
Prolonged hypoxemia requiring mechanical ventilation is common in severe MERS cases. Secondary bacterial infections may prolong hospitalization and complicate recovery. Acute kidney injury may require temporary renal replacement therapy. Neurological complications such as encephalopathy can occur during acute illness.	Pulmonary fibrosis and chronic lung impairment may develop after severe pneumonia. Persistent fatigue and reduced exercise tolerance are reported in survivors. Psychological sequelae including post-traumatic stress disorder can occur after critical illness. Chronic kidney disease may persist following acute kidney injury.

Differential Diagnoses

Middle East Respiratory Syndrome (MERS) (Coronaviruses) versus Severe Acute Respiratory Syndrome (SARS)

Middle East Respiratory Syndrome (MERS) (Coronaviruses)	Severe Acute Respiratory Syndrome (SARS)
Exposure to dromedary camels or travel to Arabian Peninsula	Exposure to civet cats or travel to Guangdong province, China
Infection with MERS-CoV coronavirus	Infection with SARS-CoV coronavirus
Variable progression with often severe respiratory illness and higher mortality	Rapid progression to respiratory failure within 7-10 days

Middle East Respiratory Syndrome (MERS) (Coronaviruses) versus Influenza Virus Infection

Middle East Respiratory Syndrome (MERS) (Coronaviruses)	Influenza Virus Infection
Sporadic cases linked to camel exposure or healthcare settings	Seasonal outbreaks with widespread community transmission
Positive RT-PCR specific for MERS-CoV RNA	Positive rapid influenza diagnostic test or PCR for influenza A/B
Often severe pneumonia with high mortality and prolonged hospitalization	Usually self-limited illness with rapid symptom resolution

Middle East Respiratory Syndrome (MERS) (Coronaviruses) versus COVID-19 (SARS-CoV-2 Infection)

Middle East Respiratory Syndrome (MERS) (Coronaviruses)	COVID-19 (SARS-CoV-2 Infection)
Infection with MERS-CoV coronavirus	Infection with SARS-CoV-2 coronavirus
Exposure to camels or limited human-to-human transmission in Middle East	Exposure to infected humans with global pandemic spread
Positive RT-PCR for MERS-CoV RNA	Positive RT-PCR for SARS-CoV-2 RNA

Middle East Respiratory Syndrome (MERS) (Coronaviruses) versus Bacterial Pneumonia

Middle East Respiratory Syndrome (MERS) (Coronaviruses)	Bacterial Pneumonia
Normal or mildly elevated procalcitonin with lymphopenia	Elevated procalcitonin and neutrophilic leukocytosis
Bilateral patchy infiltrates or ground-glass opacities	Lobar consolidation on chest X-ray
Poor response to antibiotics, requiring supportive care and antivirals	Improvement with empiric antibiotics

Middle East Respiratory Syndrome (MERS) (Coronaviruses) versus Other Viral Pneumonias (e.g., RSV, Adenovirus)

Middle East Respiratory Syndrome (MERS) (Coronaviruses)	Other Viral Pneumonias (e.g., RSV, Adenovirus)
Primarily affects adults and older individuals	Primarily affects infants and young children
Infection with MERS-CoV coronavirus	Infection with respiratory syncytial virus or adenovirus
Often severe respiratory illness with high mortality	Usually mild to moderate illness with self-limited course